Nurix Therapeutics, Inc.
Financial highlights
| Metric | FY 11/30/25 | FY 11/30/24 | FY 11/30/23 | FY 11/30/22 | FY 11/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $84.0M | $54.5M | $77.0M | $38.6M | $29.8M |
| Research and development | $316.9M | $221.6M | $189.1M | $184.5M | $116.4M |
| Operating expenses | $369.6M | $267.6M | $232.1M | $222.5M | $147.6M |
| Operating income | -$285.7M | -$213.0M | -$155.1M | -$183.9M | -$117.9M |
| Pretax income | -$263.7M | -$193.3M | -$143.9M | -$180.4M | -$117.1M |
| Income tax expense | $760,000 | $270,000 | $0 | $0 | $131,000 |
| Net income | -$264.5M | -$193.6M | -$143.9M | -$180.4M | -$117.2M |
| Balance Sheet | |||||
| Cash and equivalents | $247.0M | $110.0M | $54.6M | $64.5M | $80.5M |
| Current assets | $606.8M | $619.4M | $295.5M | $318.4M | $311.1M |
| Total assets | $688.1M | $669.3M | $355.6M | $416.8M | $476.8M |
| Current liabilities | $86.5M | $95.9M | $87.0M | $70.7M | $66.3M |
| Total liabilities | $149.4M | $142.3M | $155.1M | $113.1M | $134.5M |
| Stockholders' equity | $538.7M | $527.0M | $200.5M | $303.7M | $342.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$249.5M | -$172.6M | -$81.4M | -$159.8M | -$84.4M |
| Depreciation and amortization | $8.7M | $9.3M | $7.5M | $5.3M | $2.8M |
| Stock-based compensation | $38.0M | $33.9M | $33.7M | $28.1M | $15.8M |
| Capital expenditure | $14.0M | $9.3M | $8.4M | $12.2M | $5.7M |
| Free cash flow | -$263.5M | -$181.9M | -$89.8M | -$172.1M | -$90.0M |
| Share repurchases | — | — | — | — | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 103.4M · Free float 92.9%
Annual filing data through FY ended November 30, 2025; float as of July 14, 2026.